BioTech

GSK Decides Not To Progress Development Of Camlipixant In Refractory Chronic Cough

July 17, 2026 — 05:32 am EDT

Written by RTTNews.com for RTTNews

(RTTNews) - GSK plc (GSK, GSK.L) issued an update on the CALM-1 and CALM-2 phase III clinical trials, which assessed the efficacy and safety of two doses of camlipixant in adults with refractory chronic cough. The company said, based on the aggregate data, the limited efficacy demonstrated is unlikely to transform patient care. GSK has decided not to progress further development of camlipixant in refractory chronic cough.

CALM-1 met its primary endpoint with camlipixant 50mg twice daily showing statistically significant reductions in 24-hour cough frequency versus placebo at week 12. CALM-2 did not reach statistical significance in the same primary endpoint with 50mg twice daily at week 24.

GSK shares are trading at 1,898.00 pence, down 2.97%.

For More Such Health News, visit rttnews.com.

RTTNews

Founded in the late 1990s by Andrew Mariathasan in New York, with the goal of covering Wall Street for a new generation of investors, RTTNews has expanded steadily over the years to become a trusted provider of content for a wide array of subjects across several platforms. RTT's Financial Newswire is relied upon by some of the world's largest financial institutions, including banks, brokerages, trading platforms and financial exchanges.

GSK Decides Not To Progress Development Of Camlipixant In Refractory Chronic Cough

Tags

Latest Articles